hu14.18K322A at St. Jude Children's hospital showing promising results

(Sam Saffron) #1

St Jude are presenting data about hu14.18K322A a less painful variant of ch14.18 that can be used in frontline chemotherapy.

Immunotherapy has an effect on measurable disease
(Sam Saffron) #2

Dr. Sara Federico had an extensive talk about this antibody and usage at St. Judes

One very interesting outcome is an upcoming clinical trial in COG that introduces antibody treatment in frontline chemo in cycles 3-5.